Literature DB >> 1380765

The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE).

C Bolton1.   

Abstract

The in vitro potency of the immunosuppressants Cyclosporin A (CsA), FK-506 and Prednisolone was assessed using the adoptive transfer model of EAE in the Lewis rat. Co-culture of encephalitogen-sensitised splenic leukocytes with Prednisolone did not inhibit the transfer of disease to naive histocompatible recipients despite significant suppression of neuroantigen-stimulated leukocyte proliferation by the drug. The addition of CsA (100 nM) to cultures inhibited the induction of adoptive EAE but a lower dose of the agent (10 nM) did not prevent the development of clinico-histopathological signs of disease. FK-506 (1 nM) was 100 times more effective than CsA at suppressing adoptive EAE thus emphasising the usefulness of the model in determining the relative efficacy of compounds to modify cell-dependent autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380765     DOI: 10.1007/bf01990955

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  26 in total

1.  Interferon in experimental autoimmune encephalomyelitis (EAE): effects of exogeneous interferon on the antigen-enhanced adoptive transfer of EAE.

Authors:  S L Abreu
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

2.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

3.  Effects of FK-506 on collagen arthritis in mice.

Authors:  K Takagishi; M Yamamoto; A Nishimura; G Yamasaki; N Kanazawa; T Hotokebuchi; N Kaibara
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

4.  Immunosuppressive effect of FK506 on collagen-induced arthritis in rats.

Authors:  N Inamura; M Hashimoto; K Nakahara; H Aoki; I Yamaguchi; M Kohsaka
Journal:  Clin Immunol Immunopathol       Date:  1988-01

5.  Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus.

Authors:  K Takabayashi; T Koike; K Kurasawa; R Matsumura; T Sato; H Tomioka; I Ito; T Yoshiki; S Yoshida
Journal:  Clin Immunol Immunopathol       Date:  1989-04

6.  T lymphocyte line-mediated experimental allergic encephalomyelitis--a pharmacologic model for testing of immunosuppressive agents for the treatment of autoimmune central nervous system disease.

Authors:  M E Westarp; H Wekerle; A Ben-Nun; I R Cohen; M L Vohl; H Przuntek
Journal:  J Pharmacol Exp Ther       Date:  1987-08       Impact factor: 4.030

7.  The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.

Authors:  A Ben-Nun; H Wekerle; I R Cohen
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

8.  Relevance of experimental allergic encephalomyelitis to multiple sclerosis.

Authors:  B G Arnason
Journal:  Neurol Clin       Date:  1983-08       Impact factor: 3.806

9.  Pharmacological comparison of active and passive experimental allergic encephalomyelitis in the rat.

Authors:  S Desai; R Barton
Journal:  Agents Actions       Date:  1989-06

10.  Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats.

Authors:  H Kawashima; Y Fujino; M Mochizuki
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-08       Impact factor: 4.799

View more
  1 in total

Review 1.  Therapeutic potential of protein kinase C inhibitors.

Authors:  D Bradshaw; C H Hill; J S Nixon; S E Wilkinson
Journal:  Agents Actions       Date:  1993-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.